Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Mar 23;8(3):245-53.
doi: 10.7150/ijms.8.245.

Current status of methods to assess cancer drug resistance

Theodor H Lippert  1 , Hans-Jörg Ruoff, Manfred Volm
Affiliations
Review

Current status of methods to assess cancer drug resistance

Theodor H Lippert et al. Int J Med Sci. .

Abstract

Drug resistance is the main cause of the failure of chemotherapy of malignant tumors, resistance being either preexisting (intrinsic resistance) or induced by the drugs (acquired resistance). At present, resistance is usually diagnosed during treatment after a long period of drug administration.In the present paper, methods for a rapid assessment of drug resistance are described. Three main classes of test procedures can be found in the literature, i.e. fresh tumor cell culture tests, cancer biomarker tests and positron emission tomography (PET) tests. The methods are based on the evaluation of molecular processes, i.e. metabolic activities of cancer cells. Drug resistance can be diagnosed before treatment in-vitro with fresh tumor cell culture tests, and after a short time of treatment in-vivo with PET tests. Cancer biomarker tests, for which great potential has been predicted, are largely still in the development stage. Individual resistance surveillance with tests delivering rapid results signifies progress in cancer therapy management, by providing the possibility to avoid drug therapies that are ineffective and only harmful.

Keywords: cancer biomarker tests; cancer drug resistance; in vitro cancer drug resistance tests; in vivo cancer drug resistance tests.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have declared that no conflict of interest exists.

Figures

Fig 1
Fig 1
Schematic procedure of fresh tumor cell culture assays.
Fig 2
Fig 2
Different fields with sub-areas necessary for data analysis algorithms for fingerprint detection of cancer biomarkers
Fig 3
Fig 3
Schematic illustration of quantitative cancer image analysis in positron-emission tomography.
See this image and copyright information in PMC

References

    1. Pinedo HM, Giaccone G. Drug Resistance in the Treatment of Cancer. Cambridge: Cambridge University Press; 1998.
    1. Lippert TH, Ruoff HJ, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittel-Forschung. 2008;58:261–264. - PubMed
    1. Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: A complex and integrated cellular response. Pharmacology. 2008;81:275–300. - PubMed
    1. Widakowich C, de Castro G, de Azambuja E, Dink P, Awada A. Review: Side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007;12:1443–1455. - PubMed
    1. Tanneberger St. Gewebekultur und Krebschemotherapie. Arch Geschwulstforsch. 1968;31:387–400. - PubMed

MeSH terms